|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Eprosartan#Drug Interactions]] |
| {{Eprosartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| ===Dual Blockade of the Renin-[[angiotensin ]]System (RAS)===
| |
| | |
| Dual blockade of the RAS with [[[[angiotensin ]]receptor blockers]], [[ACE inhibitors]], or [[aliskiren]] is associated with increased risks of [[hypotension]], [[hyperkalemia]], and changes in renal function (including [[acute renal failure]]) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on TEVETEN and other agents that affect the RAS.
| |
| | |
| Do not co-administer [[aliskiren]] with TEVETEN in patients with diabetes. Avoid use of aliskiren with TEVETEN in patients with renal impairment (GFR <60 ml/min).
| |
| | |
| Eprosartan has been shown to have no effect on the pharmacokinetics of [[digoxin]] and the pharmacodynamics of [[warfarin]] and [[glyburide]]. Thus, no dosing adjustments are necessary during concomitant use with these agents. Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and [[ketoconazole]] and [[fluconazole]], potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics. Ranitidine also has no effect on eprosartan pharmacokinetics.
| |
| | |
| Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a [[thiazide]] [[diuretic]] ([[hydrochlorothiazide]]). Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release [[calcium channel blockers]] (sustained-release nifedipine) with no clinically significant adverse interactions.
| |
| | |
| ===Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)===
| |
| | |
| In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with [[angiotensin ]]II receptor antagonists, including eprosartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving eprosartan and NSAID therapy.
| |
| | |
| The antihypertensive effect of [[angiotensin ]]II receptor antagonists, including eprosartan may be attenuated by NSAIDs including selective COX-2 inhibitors.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TEVETEN (EPROSARTAN MESYLATE) TABLET [ABBOTT LABORATORIES] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7cde57a7-eded-4c22-b1c7-98afc5546997 | publisher = | date = | accessdate = 20 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{angiotensin II receptor antagonists}}
| |
| | |
| [[Category:angiotensin II receptor antagonists]]
| |
| [[Category:Imidazoles]]
| |
| [[Category:Thiophenes]]
| |
| [[Category:Benzoic acids]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |